Effects of 0.05% cyclosporine, diquafosol sodium, and perfluorohexyloctane eye drops on ocular surface parameters after cataract surgery in patients with type 2 diabetes: a randomized controlled trial
In brief
After cataract surgery, cyclosporine adds 5 seconds to tear break-up time
In this trial of patients with type 2 diabetes, cyclosporine improved tear break-up time by 5 seconds versus standard care at 4 weeks. Diquafosol improved tear production and tear quality measures, while perfluorohexyloctane showed no clear benefit on the measured outcomes. Only 120 of 144 patients completed follow-up, and these short-term objective signs do not establish which treatment is best.
- Journal
- Frontiers in medicine (Q1)
- Published
- 29 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Han Jiang, Meng Ma, Luolei Wang, Shuangle Li
- PMID
- 43021834
- DOI
- 10.3389/fmed.2026.1960289
Why clinicians should know about it
- Picked for Ophthalmology (top studies of the week, 15 November 2026): Randomized trial evaluates ocular surface treatment after cataract surgery
Abstract
OBJECTIVE: To compare the short-term effects of cyclosporine, diquafosol sodium, and perfluorohexyloctane on objective ocular surface parameters after cataract surgery in patients with type 2 diabetes. METHODS: In this prospective randomized trial, 144 patients with type 2 diabetes (144 eyes) were randomly assigned to receive standard postoperative care alone or with adjunctive 0.05% cyclosporine, 3% diquafosol sodium, or perfluorohexyloctane eye drops. Of these, 120 (83.3%) completed the 4-week follow-up and were included in the per-protocol analysis. Tear film lipid layer thickness (LLT), tear break-up time (BUT), tear meniscus height (TMH), tear ferning grade, and Schirmer I test (SIT) values were assessed preoperatively and on postoperative day 1 and at weeks 1, 2, 3, and 4. Baseline glycated hemoglobin (HbA1c), diabetes duration, and insulin use were explored as potential modifiers of treatment effects. RESULTS: Treatment-by-time interactions were observed for all five outcomes (all P < 0.001). After multiplicity adjustment, cyclosporine showed a greater increase in BUT than standard control at week 4 (difference, 5.0 s; adjusted CI, 2.7-7.0). Diquafosol showed greater reductions in tear ferning grade and greater increases in Schirmer I values at weeks 3 and 4. At week 4, the respective differences were -1.0 grade (adjusted CI, -2.5 to -1.0) and 5.0 mm (1.0-7.0). No adjusted LLT or TMH comparison interval excluded zero. CONCLUSIONS: Compared with standard care, 0.05% cyclosporine yields short-term improvements in BUT, and diquafosol sodium produces short-term benefits in the Schirmer I test and tear ferning grade. These findings are limited to objective signs and cannot establish an overall treatment ranking among the three agents. TRIAL REGISTRATION: Chinese Clinical Trial Registry https://www.chictr.org.cn/bin/project/edit?pid=265508, ChiCTR2500099433. Reg date: 2025-03-24.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.